Payment overview · 2025
General Payments
$599.50
28 reported records · 13 companies
Healthcare provider profile · identity verified
Richard E Roby, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LUFKIN, TX · NPI 1518073121
Verified facts
What the public records show
CMS Open Payments records show Richard E Roby, MD received $599.50 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.05 | 16.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $86.85 | 14.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.81 | 12.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.78 | 11.8% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.48 | 11.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.22 | 7.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.70 | 5.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26.61 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.53 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.90 | 3.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.70 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.57 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.30 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $599.50 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $86.85 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.22 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.81 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.48 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.09 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.75 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.03 | 2 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 108 |
| Losartan Potassium | Losartan Potassium | 296 | 82 |
| Lisinopril | Lisinopril | 266 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 56 |
| Gabapentin | Gabapentin | 228 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 72 |
| Eliquis | Apixaban | 199 | 36 |
| Metformin Hcl | Metformin Hcl | 196 | 54 |
| Furosemide | Furosemide | 195 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 55 |
| Simvastatin | Simvastatin | 183 | 47 |
| Potassium Chloride | Potassium Chloride | 182 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 46 |
| Carvedilol | Carvedilol | 153 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 40 |
| Glimepiride | Glimepiride | 118 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 28 |
| Ezetimibe | Ezetimibe | 112 | 34 |
| Cephalexin | Cephalexin | 111 | 74 |
| Irbesartan | Irbesartan | 111 | 31 |
| Metformin Hcl Er | Metformin Hcl | 105 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 26 |
| Omeprazole | Omeprazole | 102 | 30 |
| Mounjaro | Tirzepatide | 87 | 14 |
| Nifedipine Er | Nifedipine | 84 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 17 |
| Trulicity | Dulaglutide | 68 | suppressed |
| Valsartan | Valsartan | 64 | 17 |
| Prednisone | Prednisone | 59 | 22 |
| Alprazolam | Alprazolam | 58 | 12 |
| Finasteride | Finasteride | 58 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 12 |
| Sertraline Hcl | Sertraline Hcl | 53 | 14 |
| Atenolol | Atenolol | 47 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 12 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Estradiol | Estradiol | 35 | 12 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Clonidine | Clonidine | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Allopurinol | Allopurinol | 26 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $599.50 · 28 records | Novo Nordisk Inc | CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, IMBRUVICA, JARDIANCE, LEQVIO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Wegovy, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error